SCHEMBL3714726

SCHEMBL3714726

O=C(O)NCCc1nc2ncc(Br)cc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
MAPK10 P53779 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.49
NOS3 P29474 1/20 0.47
NOS1 P29475 1/20 0.47
NOS2 P35228 1/20 0.47
NPSR1 Q6W5P4 2/20 0.45
HPGD P15428 2/20 0.45
RXFP1 Q9HBX9 5/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
PKM P14618 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12647714 0.75 ALDH1A1 (0.47) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1
SCHEMBL16176491 0.75 HTT (0.51) SMN1; SMN2LMNAHTTMAPT
SCHEMBL4051158 0.74 ALDH1A1 (0.57) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1
SCHEMBL3714725 0.74 ALDH1A1 (0.54) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1
SCHEMBL4060448 0.72 ALDH1A1 (0.58) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1
SCHEMBL10079650 0.72 SMN1; SMN2 (0.57) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1
SCHEMBL4053617 0.72 NOS3 (0.57) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1
SCHEMBL856556 0.72 ALDH1A1 (0.57) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1
SCHEMBL1507303 0.72 ALDH1A1 (0.60) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1
SCHEMBL4053179 0.71 ALDH1A1 (0.54) ALDH1A1MAPK10SMN1; SMN2NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3533/4885MAPK10 49/4885SMN1; SMN2 3818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.